BiotechTube
Tessellate BIO

Tessellate BIO

Leiden, Netherlands· Est.
tessellatebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Tessellate Bio is an early-stage biotech pioneering the next frontier of synthetic lethality in oncology, targeting mechanisms beyond the well-established HRD pathway. The company has two disclosed preclinical programs targeting Alternative Lengthening of Telomeres (ALT) and RB1 Loss-of-Function, and has secured a significant partnership with Boehringer Ingelheim. Backed by top-tier European investors and led by a seasoned team of drug hunters, Tessellate aims to create highly tumor-targeted treatments for hard-to-treat cancers.

Oncology

Technology Platform

Platform for discovering and validating novel synthetic lethal interactions beyond HRD, with integrated biomarker and companion diagnostic development.

Opportunities

The partnership with Boehringer Ingelheim provides significant validation, resources, and a de-risked path to development for a lead program.
The large, underserved patient populations with ALT-positive or RB1-loss cancers represent a substantial market opportunity for first-in-class, targeted therapies.

Risk Factors

High scientific risk in validating novel synthetic lethal biology and discovering druggable molecules.
Competitive pressure is increasing as more companies explore synthetic lethality beyond PARP.
Execution risk in advancing multiple early-stage programs with a small team.

Competitive Landscape

Tessellate operates in the growing field of synthetic lethality, competing with other biotechs (e.g., Repare Therapeutics, IDEAYA Biosciences) and large pharma exploring targets beyond HRD. Its differentiation lies in its specific focus on ALT and RB1 biology and its integrated diagnostic strategy.

More companies in Oncology (General) →More companies in Netherlands →